Medicare Benefits Schedule - Item 16018

Search Results for Item 16018

View Associated Notes

Category 3 - THERAPEUTIC PROCEDURES

16018

16018 - Additional Information

Item Start Date:
22-Dec-1999
Description Updated:
01-Jul-2023
Schedule Fee Updated:
01-Jul-2025

Group
T3 - Therapeutic Nuclear Medicine
Subgroup
1 - Administration of Nuclear Medicine

Administration of 153 Sm-lexidronam for the relief of bone pain due to skeletal metastases (as indicated by a positive bone scan), if systemic antineoplastic therapy is unavailable or has failed to control the patient’s disease, and:

a) the disease is poorly controlled by conventional radiotherapy; or

b) conventional radiotherapy is inappropriate, due to the wide distribution of sites of bone pain.

Fee: $5,128.30 Benefit: 75% = $3,846.25 85% = $5,023.80

(See para TR.3.1 of explanatory notes to this Category)

Associated Notes

Category 3 - THERAPEUTIC PROCEDURES

TR.3.1

Provider restriction for items in Group T3

Medicare benefits for items in Group T3 are only payable when the service is provided by a specialist or consultant physician with training in nuclear medicine.

Related Items: 16003 16006 16009 16012 16015 16018 16050 16055 16060

Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change